Morgan Stanley Sesen Bio, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.49 - $0.61 $78,104 - $97,231	-159,396 Reduced 22.2%	558,686 $340,000
Q3 2022 Nov 14, 2022	SELL	$0.0 - $0.93 $0 - $258,161	-277,593 Reduced 27.88%	718,082 $305,000
Q2 2022 Oct 27, 2022	BUY	$0.38 - $0.89 $282,935 - $662,664	744,567 Added 296.51%	995,675 $806,000
Q2 2022 Aug 15, 2022	BUY	$0.38 - $0.89 $282,935 - $662,664	744,567 Added 296.51%	995,675 $806,000
Q1 2022 Oct 27, 2022	SELL	$0.58 - $0.86 $431,848 - $640,327	-744,567 Reduced 74.78%	251,108 $152,000
Q1 2022 May 13, 2022	SELL	$0.58 - $0.86 $147,814 - $219,173	-254,853 Reduced 50.37%	251,108 $152,000
Q4 2021 Feb 14, 2022	SELL	$0.73 - $1.28 $107,657 - $188,769	-147,476 Reduced 22.57%	505,961 $412,000
Q3 2021 Nov 15, 2021	BUY	$0.77 - $4.91 $503,146 - $3.21 Million	653,437 New	653,437 $518,000

Ticker SESN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,702,000
Market Cap $127M
Description
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.